# Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT01441882** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Refractory Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01441882
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2016-07-12
- **Final completion:** 2018-01-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441882, "Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01441882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*